Study to Assess Analgesic Efficacy and Safety of ASP3662 in Subjects With Painful Diabetic Peripheral Neuropathy

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Painful Diabetic Peripheral Neuropathy (PDPN)

In brief

The purpose of this study is to assess analgesic efficacy of ASP3662 relative to placebo in subjects with painful diabetic peripheral neuropathy (PDPN) as well as assess the safety and tolerability of ASP3662 relative to placebo. The analgesic effect is evaluated by measuring percent responders, change in daily worst pain score, change in average daily pain score, Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC).

Key facts

Study ID: NCT02372578
Run by: Astellas Pharma Global Development, Inc.
People needed: 115
Starts: 2015-05-27
Expected to finish: 2016-05-20
Last updated by the study team: 2019-03-26

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Subject has a BMI ≤ 40.
Subject has all of the following:
Established diagnosis of diabetes (Type I or II) with painful diabetic peripheral neuropathy and glycosylated hemoglobin (HgbA1c) ≤ 9.5% at Screening or Randomization.
Stable diabetic drug regimen for at least 3 months prior to Screening.
At least a 1 year history of PDPN.
Diagnosis of PDPN to be confirmed by a score of ≥ 3 on the Michigan Neuropathy Screening Instrument (MNSI) at Screening.
Subject has pain intensity score(s) ≥ 4 or ≤ 9 on an 11-point numeric pain rating scale (NPRS) at Screening Visit and prior to Randomization.
Subject agrees to complete pain diaries and is complaint with the daily pain recording prior to Randomization as defined by the completion of a minimum of 5 of 7 daily pain ratings, 3 of which are required in the last 4 days.
Subject's anti-diabetic regimen is anticipated to be stable throughout the study.
Subject must be willing to washout of all medications currently being taken for his/her PDPN (chronic and occasional/as needed) and remain off of those pain medications while participating in the study.

You may not qualify if…

Subject has received prior treatment with pregabalin for PDPN and was considered unresponsive or intolerant.
Subject has tried and failed 3 or more drugs to treat PDPN within the past 3 years. Drugs must have been administered at therapeutic doses and have been administered for an adequate period of time.
Subject has a known hypersensitivity to ASP3662, pregabalin, gabapentin or acetaminophen, or their formulation components.
Subject has significant pain (moderate or above) due to causes other than PDPN.
Subject has a history of painful peripheral neuropathy due to a cause other than diabetes.
Subject has any lower extremity amputation
Subject has a current or previous foot ulcer within the past 3 months as described by medical history and/or medical examination.
Subject has an active malignancy or a history of malignancy (except for treated non-melanoma skin cancer) within 5 years.
Subject has clinically significant abnormalities in clinical chemistry, hematology, or urinalysis, or a serum creatinine at Screening.
Subject has creatinine clearance < 60 mL/min (estimated from serum creatinine, body weight, age, and sex using the Cockcroft and Gault equation) at Screening.
Subject tests positive for hepatitis B surface antigen (HBsAg) or hepatitis C antibody at Screening or has a known history of a positive test for human immunodeficiency virus (HIV) infection.
Subject has a positive drug screen for alcohol or drugs of abuse at Screening and/or Randomization. Subjects who are on low doses of benzodiazepines for sleep with a legitimate prescription will be allowed into the study. In addition, subjects with a positive drug screen at Randomization will be excluded.
Subject is currently using protocol specified non-permitted medications including OTC products and is unable or does not choose to discontinue them.
Subject has planned an elective surgery during planned study participation.

Where it is running

Site US10001 — Anniston, Alabama, United States
Site US10039 — Phoenix, Arizona, United States
Site US10054 — Fresno, California, United States
Site US10020 — Lomita, California, United States
Site US10047 — Santa Monica, California, United States
Site US10017 — Tustin, California, United States
Site US10055 — Walnut Creek, California, United States
Site US10053 — Fairfield, Connecticut, United States
Site US10005 — Boynton Beach, Florida, United States
Site US10023 — Bradenton, Florida, United States
Site US10018 — Clearwater, Florida, United States
Site US10019 — DeLand, Florida, United States
Site US10004 — Homestead, Florida, United States
Site US10042 — Jacksonville, Florida, United States
Site US10007 — Jupiter, Florida, United States
Site US10041 — Miami Lakes, Florida, United States
Site US10046 — Orlando, Florida, United States
Site US10008 — Ormond Beach, Florida, United States
Site US10003 — Oviedo, Florida, United States
Site US10049 — The Villages, Florida, United States
Site US10009 — Aurora, Illinois, United States
Site US10036 — Chicago, Illinois, United States
Site US10025 — Evansville, Indiana, United States
Site US10064 — Metairie, Louisiana, United States
Site US10051 — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.